Vol 14, No 1 (2021)
Review paper
Published online: 2021-09-30
Nephrotoxicity of immune checkpoint inhibitors in immunotherapy of oncologic patients
Renal Disease and Transplantation Forum 2021;14(1).
Abstract
Not available
Keywords: checkpoints inhibitorskidney injury
References
- Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020; 97(1): 62–74.
- Perazella MA, Shirali AC. Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. J Am Soc Nephrol. 2018; 29(8): 2039–2052.
- Oleas D, Bolufer M, Agraz I, et al. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J. 2021; 14(5): 1364–1370.
- Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron. 2012; 120(4): c179–c184.
- Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020; 31(2): 435–446.
- Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist. 2019; 24(6): 735–742.
- Kostine M, Rouxel L, Barnetche T, et al. FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018; 77(3): 393–398.
- Meraz-Muñoz A, Amir E, Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020; 8(1).
- Malyszko J, Tesarova P, Capasso G, et al. The link between kidney disease and cancer: complications and treatment. Lancet. 2020; 396(10246): 277–287.
- Shingarev R, Glezerman IG. Kidney Complications of Immune Checkpoint Inhibitors: A Review. Am J Kidney Dis. 2019; 74(4): 529–537.
- Malyszko J, Lee MW, Capasso G, et al. How to assess kidney function in oncology patients. Kidney Int. 2020; 97(5): 894–903.
- Brahmer JR, Lacchetti C, Thompson JA, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17): 1714–1768.
- Strohbehn IA, Lee M, Seethapathy H, et al. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. Am J Kidney Dis. 2020; 76(2): 299–302.
- Grzejszczak P, Kurnatowska I. Czynniki ryzyka oraz epidemiologia nowotworów u chorych po przeszczepach narządowych. in: Durczyński A, Hogendorf P (red.) Nowotwory po przeszczepieniu narządów. Biblioteka chirurga onkologa. Tom 19. Via Medica Gdańsk. ; 2020: 3–10.
- Kumar V, Shinagare AB, Rennke HG, et al. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist. 2020; 25(6): 505–514.
- Manohar S, Thongprayoon C, Cheungpasitporn W, et al. Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney Int Rep. 2020; 5(2): 149–158.
- Venkatachalam K, Malone AF, Heady B, et al. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients. Transplantation. 2020; 104(5): 1041–1047.
